Zydus receives US FDA approval for Zituvimet to treat adult patients with type 2 diabetes mellitus

Zydus Lifesciences Limited announced that the US Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Zituvimet (sitagliptin and metformin hydrochloride) tablets, 50 mg/500 mg and 50 mg/1000 mg.

Zituvimet contains active ingredients sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

The approval of Zituvimet is based on research, development, regulatory, and manufacturing work performed by Zydus teams. Zituvimet has undergone quality testing for nitrosamines and potential genotoxic impurities as per current US FDA standards. Zituvimet is compliant with current US FDA standards of Nitrosamines in sitagliptin containing products.

“The Zituvimet approval further builds on our previous approval of Zituvio (sitagliptin) and offers an increased accessibility and affordability to healthcare systems with regard to prescription drugs for type II diabetes. The Zituvimet approval provides an affordable treatment option for healthcare systems to reduce the rate of growth in drug spending and improves the financial sustainability of the healthcare programmes,” said Dr Sharvil Patel, managing director of Zydus Lifesciences Limited.

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!